Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Introduction: Historically, renal cell carcinoma (RCC) is considered a chemotherapy-resistant tumor. The cornerstone of systemic therapy included mammalian target of rapamycin (mTOR) inhibitors, endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitors (TKIs). Currently, a new era is...
| Publicado en: | Expert Review of Anticancer Therapy Vol. 17; no. 4; pp. 357 - 369 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Taylor & Francis Ltd
Apr2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |